NuPharm Group rebrands to Neuraxpharm
The European specialty pharmaceutical company launches its new name to support its strategic vision
October 3, 2018. Neuraxpharm, a leading European specialty pharmaceutical company, is pleased to announce its new name, having rebranded from NuPharm Group. This exciting next chapter for the company positions Neuraxpharm as a single and differentiated CNS-oriented firm within the European pharmaceutical industry.
Neuraxpharm develops and commercializes branded and generic pharmaceuticals for the treatment of disorders that affect the central nervous system (CNS). With over 100 CNS molecules, the company offers a wide range of effective, differentiated and affordable CNS treatment options to patients, healthcare professionals and industry partners. Neuraxpharm has a direct presence in Germany, Spain, Italy, France and Poland, and plans further geographic expansion in the near term as part of its strategy to strengthen its position as a European leader in CNS treatments.
Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: “We are delighted to launch the company as Neuraxpharm today. Neuraxpharm is the existing name of our German affiliate, which has been a major player in the CNS market since 1985, and so rebranding our European affiliates within the next months under this name leverages this important history and excellent reputation, while also uniting all our companies together under a shared name and vision.
“We believe this development further reinforces our market position as a European market leader in pharmaceutical products for the treatment of the central nervous system. As one company with one easily identifiable and unique brand, our aim is to become the first partner of choice in CNS.”
Neuraxpharm is a leading European specialty pharmaceutical company in the treatment of central nervous system disorders (CNS) with a direct presence in Germany, Spain, Italy, France and Poland. Consolidated as a group in 2016 and backed by funds advised by Apax Partners, Neuraxpharm has a unique understanding of the CNS market of over 30 years.
Neuraxpharm develops and commercializes in Europe branded and generic CNS pharmaceuticals and nutraceuticals, offering a wide range of effective, differentiated and affordable CNS treatments, aimed at patients as well as health professionals and industry partners.
Present in more than 50 countries, Neuraxpharm also manufactures pharmaceutical forms and active pharmaceutical ingredients indicated for the CNS and respiratory areas.
For more information, contact ATREVIA:
Sergi Muñoz – email@example.com +34 667 631 681
Cristina Massana – firstname.lastname@example.org +34 689 046 835